Your browser doesn't support javascript.
loading
Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies.
Zhang, Chaoting; Palashati, Heyilimu; Rong, Zhuona; Lin, Ningjing; Shen, Luyan; Liu, Ying; Li, Shance; Yu, Bentong; Yang, Wenjun; Lu, Zheming.
Afiliação
  • Zhang C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Palashati H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Rong Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Lin N; Key Laboratory of Carcinogenesis and Translational Research, Departments of Lymphoma, Radiology and Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
  • Shen L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Li S; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Yu B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. yubentong@126.com.
  • Yang W; Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Jiangxi, 330006, China. yubentong@126.com.
  • Lu Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. ywj007@yeah.net.
Mol Cancer ; 19(1): 162, 2020 11 21.
Article em En | MEDLINE | ID: mdl-33218364
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_leukemia Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Leucemia de Células T / Imunoterapia Adotiva / Depleção Linfocítica / Citotoxicidade Imunológica Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Mol Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_leukemia Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Leucemia de Células T / Imunoterapia Adotiva / Depleção Linfocítica / Citotoxicidade Imunológica Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Mol Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China